Trial Coordinator: Kathryn Monson
Lead Researcher: Sue Catt
PrefHer was an industry-funded, multi-centre study, examining patient preference between two methods of administering an important breast cancer drug. This crossover study was conducted across 12 countries using pre- and post-treatment questionnaires to determine which method of administration patients prefer. The study evaluated the experiences and satisfaction of health care professionals with the two methods, and explored the factors influencing patient preference.
Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study Presented at the European Society for Medical Oncology 2016 (ESMO) Congress, 7–11th October 2016 in Copenhagen.
Patient preference for subcutaneous versus intravenous adjuvant trastuzumab: Results of the PrefHer Study. Presented at the 13th St. Gallen International Breast Cance Conference, 13-16th March 2013.
Reasons for patients' preferences for subcutanous or intravenous trastuzumab in the PrefHer study. Presented at the European Cancer Congress 2013 (ECCO-ESMO-ESTRO), 27th September - 1st October 2013.